The New York Times reports that ongoing turmoil at FDA has increasingly placed commissioner Marty Makary under the microscope, raising concerns among public health experts and the biotech industry.
FDA faces Increased scrutiny of its newly established Commissioner’s National Priority Review voucher program, which is intended to accelerate the review of select drug applications, because of political interference concerns.
The New York Times reports that ongoing turmoil at FDA has increasingly placed commissioner Marty Makary under the microscope, raising concerns among public health experts and the biotech industry.
FDA faces Increased scrutiny of its newly established Commissioner’s National Priority Review voucher program, which is intended to accelerate the review of select drug applications, because of political interference concerns.
FDA Webview closes its newsroom for the end-of-year Holiday Season, reopening Monday, Jan 5, 2026.
FDA posts an updated guidance outlining its processes for bioresearch monitoring inspections, which oversee the conduct, reporting, and postmarketing activities of FDA-regulated clinical and nonclinical studies.
